Introduction

The use of biosimilars for the treatment of patients with chronic inflammatory bowel diseases (IBD) showed to be a valid strategy to reduce the economic burden of biologics on health-care costs and to increase patient access to treatment. However, the nocebo effect constitutes an important limitation to the wide use of biosimilars.

Areas covered

We conducted a literature overview to summarize information on nocebo effect in IBD population and to provide physicians with practical key strategies to prevent the nocebo effect in daily clinical practice and to improve patients’ outcomes.

Expert opinion

Despite the proven efficacy and safety of biosimilars, further clinical studies are needed to define the effects of reverse and multiple switches in the management of IBD patients. The development of new subcutaneous formulations, better accepted by patients, could contribute to reduce patients’ negative expectations, and limit the nocebo effect.

中文翻译：

---

Nocebo效应和生物仿制药在炎症性肠病中的作用：新变化和下一步？

介绍

使用生物仿制药治疗慢性炎症性肠病（IBD）是减少生物制剂对医疗保健成本的经济负担并增加患者获得治疗的有效策略。但是，nocebo效应对生物仿制药的广泛使用构成了重要限制。

覆盖区域

我们进行了文献综述，以总结有关IBD人群中Nocebo效应的信息，并为医生提供实用的关键策略，以预防日常临床实践中的Nocebo效应并改善患者的预后。

专家意见

尽管已经证明了生物仿制药的功效和安全性，但仍需要进一步的临床研究来确定反向和多重转换对IBD患者管理的影响。新的皮下制剂的开发，被患者更好地接受，可能有助于降低患者的负面期望，并限制Nocebo的作用。